Defence Therapeutics Announces Warrant Terms Amendment
MWN-AI** Summary
Defence Therapeutics Inc., a Montreal-based biotechnology firm specializing in precise drug delivery systems, recently announced an amendment to the terms of 800,000 Common Share purchase warrants originally issued during a private placement in 2024. The company confirmed that the expiry of these warrants would be extended by an additional 12 months, with the new expiry dates set for October 30, 2027, and November 29, 2027. The exercise price for these warrants will be reduced from $1.00 to $0.75 per Common Share. As of the announcement date, none of the warrants have been exercised.
The adjustments consist of two sets of warrants: 775,000 set to expire on October 30, 2026, and an additional 25,000 expiring on November 29, 2026. While all other terms of the warrants will remain unchanged, it's significant to note that any warrants issued as compensation or finder warrants are not eligible for these amendments under the regulations of the Canadian Securities Exchange (CSE). This recent decision, however, is still pending final approval from the CSE.
Defence Therapeutics aims to revolutionize cancer treatment through its innovative Accum® precision drug delivery platform, which enhances the efficacy of antibody-drug conjugates (ADCs) and other biologics while minimizing side effects. The company collaborates with various pharmaceutical entities to ensure that advanced therapeutic solutions are more accessible to patients.
As investors consider this amendment in the context of the overall market, they are reminded that forward-looking statements included in the announcement carry inherent risks and uncertainties that could affect actual outcomes.
MWN-AI** Analysis
Defence Therapeutics Inc. recently announced a strategic amendment to its warrant terms, extending the expiry date of 800,000 common share purchase warrants and reducing the exercise price significantly from $1.00 to $0.75. This move is notable as it aims to enhance liquidity for shareholders and incentivize the exercise of these warrants, potentially boosting the company’s cash reserves as it embarks on further developments in its biotechnological research.
The decision to extend the expiry of the warrants by 12 months provides existing warrant holders additional time to consider exercising their rights, especially given the lowered exercise price. This could result in more substantial cash influx for Defence Therapeutics, allowing the company to accelerate its R&D efforts in precision drug delivery systems specifically aimed at enhancing cancer treatment efficacy. The current biotechnology sector has shown a robust performance trajectory, with heightened investor interest driven by advanced therapeutic innovations.
From a market perspective, shareholders should view this development as a positive signal of the company's commitment to enhancing shareholder value and financial stability. The amendment aligns with broader market trends, where biotech firms actively seek to engage their investor base through such financial instruments. However, potential and current investors should remain vigilant regarding the intrinsic risks reflected in the biotech sector, including regulatory challenges and the nascent stage of many therapeutic developments.
Investing in Defence Therapeutics could be considered by those bullish on the oncology market and innovative drug delivery technologies. The current share price at $0.75 presents a lower entry point for risk-tolerant investors who believe in the potential upside of the ongoing projects under Defence's promising pipeline. Ultimately, monitoring market sentiment and the company's upcoming developments will be crucial in making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a total of 800,000 Common Share purchase warrants (the "Warrants") originally issued as part of a private placement closed in 2024. The expiry date will be extended by 12 months and the exercise price will be repriced at $0.75 per Common Share, as follows:
| No. of Warrants: | Original Expiry Date of Warrants: | New Expiry Date of Warrants: | Original Exercise Price of Warrants: | New Exercise Price of Warrants: |
| 775,000 | October 30, 2026 | October 30, 2027 | $1.00 | $0.75 |
| 25,000 | November 29, 2026 | November 29, 2027 | $1.00 | $0.75 |
None of the Warrants have been exercised as of the date hereof. All other terms of the Warrants will remain unchanged. In accordance with the requirements of the Canadian Securities Exchange, the terms of any warrants issued as compensation warrants or as finder warrants are not eligible for amendment. The amendments are subject to the final approval of the CSE.
About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.
For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289329
FAQ**
How does Defence Therapeutics Inc Cl A DTCFF’s recent warrant amendments impact its equity position in the Montreal biotechnology market?
What are the anticipated effects of Defence Therapeutics Inc Cl A DTCFF's initiatives on the healthcare landscape in Montreal, particularly in cancer treatment?
In what ways could the repricing of warrants for Defence Therapeutics Inc Cl A DTCFF influence investor sentiment and market performance in Montreal?
What collaborations or partnerships is Defence Therapeutics Inc Cl A DTCFF pursuing to further its drug delivery platform within the Montreal biotech community?
**MWN-AI FAQ is based on asking OpenAI questions about Defence Therapeutics Inc. Class A (CNQC: DTC:CC).
NASDAQ: DTC:CC
DTC:CC Trading
-3.59% G/L:
$3.22 Last:
2,500 Volume:
$3.23 Open:
